Oxybutynin transdermal - Allergan

Drug Profile

Oxybutynin transdermal - Allergan

Alternative Names: CS 801; Gelnique Gel 10%; Kentera; MM 801; Oxybutynin patch - Allergan; Oxybutynin topical gel - Allergan; Oxytrol

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Watson Laboratories
  • Developer Allergan; Daiichi Sankyo Company; Meiji Dairies Corporation
  • Class Alkynes; Antispasmodics; Carbocyclic acids; Cyclohexanes; Diethylamines; Esters; Mandelic acids; Small molecules
  • Mechanism of Action Cholinergic receptor antagonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Overactive bladder

Most Recent Events

  • 12 Feb 2015 Launched for Overactive bladder in Switzerland, Norway and New Zealand (Transdermal) prior to February 2015
  • 28 Feb 2014 Endo Health Solutions and Paladin Labs combine to form Endo International
  • 25 Jan 2013 The US FDA has approved the oxybutynin patch for treatment of Overactive bladder (OAB) in women as an over-the-counter (OTC) medication, as Oxytrol for Women. The product will remain available by prescription only in men with OAB
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top